KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Inventory (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Inventory data on record, last reported at $6.2 million in Q4 2025.

  • For Q4 2025, Inventory rose 2.07% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, up 2.07%, while the annual FY2025 figure was $6.2 million, 2.07% up from the prior year.
  • Inventory reached $6.2 million in Q4 2025 per AQST's latest filing, down from $7.9 million in the prior quarter.
  • Across five years, Inventory topped out at $8.1 million in Q2 2025 and bottomed at $2.8 million in Q1 2021.
  • Average Inventory over 5 years is $5.9 million, with a median of $6.4 million recorded in 2022.
  • Peak YoY movement for Inventory: decreased 11.69% in 2021, then skyrocketed 134.89% in 2022.
  • A 5-year view of Inventory shows it stood at $4.0 million in 2021, then skyrocketed by 43.14% to $5.8 million in 2022, then increased by 17.11% to $6.8 million in 2023, then dropped by 10.71% to $6.0 million in 2024, then grew by 2.07% to $6.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $6.2 million in Q4 2025, $7.9 million in Q3 2025, and $8.1 million in Q2 2025.